Skip to main content
Fig. 1 | Cerebellum & Ataxias

Fig. 1

From: Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia—a case series

Fig. 1

Percent change of the coefficient of variation (CV) of stride time under continuous treatment with Acetyl-DL-leucine. Legend: Scatter plot with individual courses of temporal gait variability before and under treatment with Acetyl-DL-leucine.14 patients showed a reduction of CV of stride time by 36 % during 1-2 weeks of treatment (1-2 weeks) and 49 % during > 4 weeks of treatment

Back to article page